Beyondspring Inc (BYSI)

$1.95 -0.10 (-4.88%)
Market Cap 82.68M
Revenue (ttm) 0.00
Net Income (ttm) -11.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 9,600
Avg Vol 39,596
Day's Range N/A - N/A
Shares Out 40.33M
Stochastic %K 55%
Beta 0.26
Analysts Strong Buy
Price Target $1.25

Company Profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Pl...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 305 6387
Address:
100 Campus Drive, 4th Floor, Suite 410 West Side, Florham Park, United States
Iightning
Iightning Nov. 19 at 11:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $BYSI Dec 19 $2 Call | Enter: $0.32 Exit: $0.57 | Profit: 80.51% ROI | https://1ightning.com
0 · Reply
balouie
balouie Nov. 16 at 3:31 PM
$BYSI This company deserves to go bankrupt. After the FDA debacle in 2021 I lost everything. To think it had fast track and priority status and wound up with nothing was nothing short of a crime.
1 · Reply
michele1twits
michele1twits Nov. 12 at 1:07 PM
$BYSI https://ca.finance.yahoo.com/news/beyondspring-reports-third-quarter-2025-120000413.html
0 · Reply
michele1twits
michele1twits Nov. 12 at 1:07 PM
$BYSI Great results!
0 · Reply
winners18
winners18 Nov. 5 at 9:50 PM
$BYSI late breaking abstract at sitc
0 · Reply
Scan8
Scan8 Oct. 24 at 11:25 PM
$BYSI They Have Realized The Prize 💎
0 · Reply
michele1twits
michele1twits Oct. 23 at 1:22 PM
$BYSI someone is playing games.
0 · Reply
XaviersLessons
XaviersLessons Oct. 23 at 6:34 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $GH $TOI $BYSI $GT Watchlist,
0 · Reply
StockScanners
StockScanners Oct. 22 at 2:06 AM
$BYSI keep watch if this holds above 2
0 · Reply
Ssssssssssssscfg
Ssssssssssssscfg Oct. 21 at 11:24 PM
$BYSI looks like people got it confused it with bynd 😂
0 · Reply
Latest News on BYSI
BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

Sep 15, 2025, 10:24 AM EDT - 2 months ago

BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

Jul 7, 2025, 7:00 AM EDT - 4 months ago

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

Jun 3, 2025, 7:00 AM EDT - 6 months ago

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:30 PM EDT - 6 months ago

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

BeyondSpring Files 2024 Annual Report on Form 10-K

Mar 27, 2025, 7:05 AM EDT - 8 months ago

BeyondSpring Files 2024 Annual Report on Form 10-K

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

Jan 28, 2025, 7:00 AM EST - 10 months ago

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

Jan 28, 2025, 7:00 AM EST - 10 months ago

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Nov 11, 2024, 8:00 AM EST - 1 year ago

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume

Oct 2, 2024, 4:11 PM EDT - 1 year ago

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Sep 3, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

Aug 6, 2024, 7:00 AM EDT - 1 year ago

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

May 16, 2024, 8:00 AM EDT - 1 year ago

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

May 3, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring Files 2023 Annual Report on Form 20-F

Apr 29, 2024, 5:30 PM EDT - 1 year ago

BeyondSpring Files 2023 Annual Report on Form 20-F

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

Apr 29, 2024, 5:30 PM EDT - 1 year ago

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Mar 25, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

Jan 10, 2024, 3:00 PM EST - 2 years ago

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Dec 18, 2023, 4:30 PM EST - 2 years ago

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor

Nov 7, 2023, 7:00 AM EST - 2 years ago

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

Oct 23, 2023, 7:45 AM EDT - 2 years ago

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting

Sep 27, 2023, 10:00 AM EDT - 2 years ago

BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

May 18, 2023, 8:30 AM EDT - 2 years ago

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

BeyondSpring Files 2022 Annual Report on Form 20-F

Apr 18, 2023, 4:30 PM EDT - 2 years ago

BeyondSpring Files 2022 Annual Report on Form 20-F

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

Apr 18, 2023, 4:30 PM EDT - 2 years ago

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

Jan 9, 2023, 4:30 PM EST - 3 years ago

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

Dec 13, 2022, 8:00 AM EST - 3 years ago

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

Sep 13, 2022, 7:00 AM EDT - 3 years ago

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

Aug 29, 2022, 7:00 AM EDT - 3 years ago

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

May 27, 2022, 7:00 AM EDT - 3 years ago

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript

Apr 14, 2022, 1:06 PM EDT - 3 years ago

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript

BeyondSpring Files 2021 Annual Report on Form 20-F

Apr 14, 2022, 9:04 AM EDT - 3 years ago

BeyondSpring Files 2021 Annual Report on Form 20-F

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

Apr 14, 2022, 7:00 AM EDT - 3 years ago

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

Apr 8, 2022, 8:00 AM EDT - 3 years ago

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

BeyondSpring Cuts On-Third Of Its Workforce

Jan 12, 2022, 5:43 AM EST - 4 years ago

BeyondSpring Cuts On-Third Of Its Workforce

BeyondSpring Announces Organizational Streamlining

Jan 11, 2022, 4:05 PM EST - 4 years ago

BeyondSpring Announces Organizational Streamlining

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Dec 30, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

Dec 15, 2021, 10:23 AM EST - 4 years ago

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

Dec 15, 2021, 7:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Dec 10, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Why BeyondSpring Shares Are Diving Today

Dec 1, 2021, 3:35 PM EST - 4 years ago

Why BeyondSpring Shares Are Diving Today

BeyondSpring Shares Crater After FDA Rejects Plinabulin Application

Dec 1, 2021, 11:06 AM EST - 4 years ago

BeyondSpring Shares Crater After FDA Rejects Plinabulin Application

BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says

Dec 1, 2021, 8:13 AM EST - 4 years ago

BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says

BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Nov 24, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Circling Back On BeyondSpring

Nov 16, 2021, 6:16 PM EST - 4 years ago

Circling Back On BeyondSpring

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

Oct 21, 2021, 7:00 AM EDT - 4 years ago

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

Iightning
Iightning Nov. 19 at 11:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $BYSI Dec 19 $2 Call | Enter: $0.32 Exit: $0.57 | Profit: 80.51% ROI | https://1ightning.com
0 · Reply
balouie
balouie Nov. 16 at 3:31 PM
$BYSI This company deserves to go bankrupt. After the FDA debacle in 2021 I lost everything. To think it had fast track and priority status and wound up with nothing was nothing short of a crime.
1 · Reply
michele1twits
michele1twits Nov. 12 at 1:07 PM
$BYSI https://ca.finance.yahoo.com/news/beyondspring-reports-third-quarter-2025-120000413.html
0 · Reply
michele1twits
michele1twits Nov. 12 at 1:07 PM
$BYSI Great results!
0 · Reply
winners18
winners18 Nov. 5 at 9:50 PM
$BYSI late breaking abstract at sitc
0 · Reply
Scan8
Scan8 Oct. 24 at 11:25 PM
$BYSI They Have Realized The Prize 💎
0 · Reply
michele1twits
michele1twits Oct. 23 at 1:22 PM
$BYSI someone is playing games.
0 · Reply
XaviersLessons
XaviersLessons Oct. 23 at 6:34 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $GH $TOI $BYSI $GT Watchlist,
0 · Reply
StockScanners
StockScanners Oct. 22 at 2:06 AM
$BYSI keep watch if this holds above 2
0 · Reply
Ssssssssssssscfg
Ssssssssssssscfg Oct. 21 at 11:24 PM
$BYSI looks like people got it confused it with bynd 😂
0 · Reply
VolcanicTrades
VolcanicTrades Oct. 21 at 10:54 PM
$BYSI 👀interesting setup
0 · Reply
michele1twits
michele1twits Oct. 21 at 8:30 PM
$BYSI what happened?
0 · Reply
TheHun
TheHun Oct. 21 at 7:49 PM
$BYSI So bullish today! Why?
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Oct. 21 at 7:15 PM
$BYSI I’m here from beyond meets. Let’s go!!!!!!
0 · Reply
balouie
balouie Oct. 19 at 12:39 PM
$BYSI This company and the idiots running it suck!! Lost everything on it when they screwed up back in 2021!!
0 · Reply
ChaseDeluca
ChaseDeluca Oct. 2 at 3:24 AM
IVDA the next 10x play nails today’s announcements and delivers over the next few quarters, even $50 is on the table. They’re working on real AI‑drone systems for security and surveillance. Today’s press added credibility. They’re no longer lab talk ….they’re going operational. $KTRA $DRCT $TALK $BYSI $PSNY
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:25 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $BYSI $RLMD $CDXS $GRO $ONL --
0 · Reply
Scan8
Scan8 Sep. 16 at 4:13 PM
$BYSI Somethings happening in China… 🇨🇳 It’s going to change everything..
0 · Reply
Scan8
Scan8 Sep. 16 at 11:08 AM
$BYSI October Surprise? An institutional investor, Geode Capital Management LLC, significantly raised its stake in BeyondSpring by 951.4%, acquiring an additional 231,844 shares.
1 · Reply
Weewooxd
Weewooxd Sep. 8 at 4:41 AM
$BYSI any updates on when new phase III trial happenin and results dropping? the run to 10 will be as soon as it does
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 10:37 AM
$BYSI Really good write-up that perfectly summarizes BYSI's present situation. So if you want to bring your BYSI knowledge up to date or just discover BYSI, this is required reading. https://beyondspx.com/quote/BYSI/beyondspring-s-dual-edged-blade-plinabulin-s-immuno-oncology-promise-and-china-market-ascent-nasdaq-bysi#analysis
1 · Reply
MidasMeme
MidasMeme Aug. 23 at 8:17 AM
$BYSI BeyondSpring Inc is a clinical stage oncology company with regulatory challenges
0 · Reply